People: CSPC Pharmaceutical Group Ltd (1093.HK)
14 Jun 2019
Mr. Li Chunlei is Executive Director of the Company. Mr. Li is currently the Chief Scientist of the Group in charge of research and development. Mr. Li is also the general manager of a subsidiary of the Company, deputy director of the Novel Pharmaceutical Preparations and Excipients State Key Laboratory and director of the Hebei Pharmaceutical Engineering Technology Centre. Mr. Li holds a bachelor’s degree in engineering (biological pharmaceutics) from Jilin University and Shenyang Pharmaceutical University, a master’s degree in science (microbial and biochemical pharmaceutics) from Jilin University and a doctorate in science (pharmaceutical science) from Shenyang Pharmaceutical University. Mr. Li is mainly engaged in the research, development and commercialisation of nano drugs, and has been responsible for the research and development of approximately 20 nano drugs including “Duomeisu” (doxorubicin hydrochloride liposome injection) and paclitaxel albumin-bound nano particles.
|Total Annual Compensation, HKD||119,000|
|Restricted Stock Award, HKD||--|
|Long-Term Incentive Plans, HKD||--|
|All Other, HKD||3,000|
|Fiscal Year Total, HKD||122,000|